| NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) | ||||||
| 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: |
Hutchison China MediTech Limited; Legal Entity Identifier: 2138006X34YDQ6OBYE79 |
|||||
| 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) | ||||||
| Non-UK issuer | X | |||||
| 2. Reason for the notification (please mark the appropriate box or boxes with an “X”) | ||||||
| An acquisition or disposal of voting rights | X | |||||
| An acquisition or disposal of financial instruments | ||||||
| An event changing the breakdown of voting rights | ||||||
| Other (please specify): | ||||||
| 3. Details of person subject to the notification obligation | ||||||
| Name | Prudential plc group of companies | |||||
| City and country of registered office (if applicable) | London, United Kingdom | |||||
| 4. Full name of shareholder(s) (if different from 3.) | ||||||
| Name | ||||||
| City and country of registered office (if applicable) | ||||||
| 5. Date on which the threshold was crossed or reached: | 25/07/2019 | |||||
| 6. Date on which issuer notified (DD/MM/YYYY): | 26/07/2019 | |||||
| 7. Total positions of person(s) subject to the notification obligation | ||||||
| % of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) |
Total of both in % (8.A + 8.B) | Total number of voting rights of issuer | |||
| Resulting situation on the date on which threshold was crossed or reached | 4.95% | 0.04% | 4.99% | 666,577,450 | ||
| Position of previous notification (if applicable) | 5.10% | 0.00% | 5.10% | |||
| 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached | |||||||||
| A: Voting rights attached to shares | |||||||||
| Class/type of sharesISIN code (if possible) |
Number of voting rights | % of voting rights | |||||||
|
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
||||||
| ORD USD0.10 KYG4672N1198 |
10,625,710 | 1.59% | |||||||
| SPON ADS US44842L1035 |
22,425,345 | 3.36% | |||||||
| SUBTOTAL 8. A | 33,051,055 | 4.95% | |||||||
| B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) | |||||||
| Type of financial instrument | Expiration datex |
Exercise/ Conversion Periodxi |
Number of voting rights that may be acquired if the instrument is exercised/converted. |
% of voting rights | |||
|
ORD USD0.10 KYG4672N1198 (Right of Recall) |
274,240 | 0.04% | |||||
| SUBTOTAL 8. B 1 | 274,240 | 0.04% | |||||
| B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) | |||||||
| Type of financial instrument | Expiration datex |
Exercise/ Conversion Period xi |
Physical or cash settlementxii |
Number of voting rights | % of voting rights | ||
| SUBTOTAL 8.B.2 | |||||||
| 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”) | ||||
| Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer | ||||
| Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) |
X | |||
| Name | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
|
Prudential plc (Parent Company) |
4.95% | 0.04% | 4.99% | |
|
M&G Prudential Limited (wholly owned subsidiary of Prudential plc) |
4.95% | 0.04% | 4.99% | |
|
M&G Group Limited (wholly owned subsidiary of Prudential plc) |
4.95% | 0.04% | 4.99% | |
|
M&G Limited (wholly owned subsidiary of M&G Group Limited) |
4.95% | 0.04% | 4.99% | |
|
M&G Investment Management Limited (wholly owned subsidiary of M&G Limited) |
4.95% | 0.04% | 4.99% | |
| 10. In case of proxy voting, please identify: | ||||
| Name of the proxy holder | N/A | |||
| The number and % of voting rights held | N/A | |||
| The date until which the voting rights will be held | N/A | |||
| 11. Additional information | ||||
| We no longer hold a notifiable interest. | ||||
| Place of completion | London, United Kingdom |
| Date of completion | 26 July 2019 |
倫敦：2019年7月30日(星期二): 和黃中國醫藥科技有限公司（Chi-Med）（AIM /納斯達克股票代碼: HCM）今天公佈截至2019年6月30日的未經審核財務數據，並公佈了關鍵臨床項目的最新進展。重點包括：
和黃中國醫藥科技主席杜志強表示:「和黃中國醫藥科技目前在各方面的經營狀況良好，未來的發展勢頭也很強勁。上半年的所有主要臨床項目數據都令人鼓舞，尤其是索凡替尼以非胰腺神經內分泌瘤為適應症的III 期臨床研究結果，以及沃利替尼治療MET外顯子14缺失的非小細胞肺癌初步研究數據完成，並預期於2019年底完成入組。我們相信這些成果有望推進和黃中國醫藥科技在今年年底及明年初分別為索凡替尼和沃利替尼提出新藥上市申請。」
「由於沃利替尼與泰瑞莎®聯合療法在治療非小細胞肺癌的初步臨床研究數據令人滿意，合作伙伴阿斯利康於今年初啟動名為SAVANNAH的全球註冊臨床研究。此外，近期公佈的沃利替尼與Imfinzi®聯合療法在治療腎癌方面的初步數據亦令人鼓舞。」
「我們首個獲批的腫瘤藥物愛優特®的銷售表現不俗。就推出後首六個月的銷售表現而言，愛優特®的銷售額遠超其他五個由跨國藥企在中國推出的小分子VEGFR抑制劑3。我們認為愛優特®憑藉其出眾的療效及安全性，加之其有望被納入國家醫保藥品目錄，假以時日將成為市場中強大的競爭者。」
「我們的商業平台如常運作。相比去年同期，按固定匯率4計算，淨收入增長9％。這筆收入為我們的臨床開發項目及研發平台提供了重要的資金。今年，我們提交了新型異檸檬酸脫氫酶 (IDH) 1/2 抑製劑6 HMPL-306的新藥臨床試驗 (IND)5 申請，為我們的腫瘤藥物管線再添第九個成員。」
「公司正在迅速發展，我們於美國新澤西的全球臨床及註冊團隊不斷壯大，以負責索凡替尼和呋喹替尼的全球註冊研究以及B細胞惡性腫瘤藥物的早期開發。我們在中國的腫瘤業務商業團隊亦在迅速擴張，負責管理醫療事務，並為明年底可能推出索凡替尼做好準備。」
「展望未來兩年，我們期望加快轉型成為一家全面綜合、面向全球的生物醫藥公司，發現、開發及商業化多種創新藥物，致力於滿足不同的醫療需求，令廣大患者受惠。」
[1]愛優特® 的中國市場的銷售額由禮來提供。
[2]間充質上皮轉化因子 (Mesenchymal Epithelial Transition Factor, MET)
[3]血管內皮生長因子受體 (Vascular Endothelial Growth Factor Receptor, VEGFR)
[4] 固定匯率(“CER”)。本公告中的若干財務資料乃按固定匯率或CER呈列。 這些財務指標並非按照美國公認會計原則（GAAP）呈報，因為它們從我們報告的結果中消除了匯率變動的影響。 請參閱下文「使用非GAAP財務指標和調節」，以獲取有關這些財務指標的解釋的相關資料，以及這些財務指標與最具可比性的GAAP指標的對賬;
[5]新藥臨床試驗 (Investigational New Drug, IND)
[6]異檸檬酸脫氫酶 (Isocitrate dehydrogenase, IDH)1和2
| 公告發佈： 7am BST (2pm HKT/2am EDT) |
| >> 查看公告 << |
| 簡報會網絡直播及電話會議： 9am BST (4pm HKT/4am EDT) |
| 觀看網絡直播回放 |
| 美國電話會議： 9am EDT (2pm BST/9pm HKT) |
| — |
To participate by phone, please use one of the following numbers. The conference ID for the calls is “Chi-Med“.
| China Toll Free | 4001 200558 |
| Hong Kong Toll Free | 800 900 476 |
| New York | +1 212 999 6659 |
| Italy Toll Free | 800 986 477 |
| Singapore Toll Free | 800 120 4789 |
| Standard International Access | +44 (0) 20 3003 2666 |
| Switzerland Toll Free | 0800 800 038 |
| UK Toll Free | 0808 109 0700 |
| USA Toll Free | 1 866 966 5335 |
| NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) | ||||||
| 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: | Hutchison China MediTech Limited; Legal Entity Identifier: 2138006X34YDQ6OBYE79 |
|||||
| 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) | ||||||
| Non-UK issuer | X | |||||
| 2. Reason for the notification (please mark the appropriate box or boxes with an “X”) | ||||||
| An acquisition or disposal of voting rights | X | |||||
| An acquisition or disposal of financial instruments | ||||||
| An event changing the breakdown of voting rights | ||||||
| Other (please specify): | ||||||
| 3. Details of person subject to the notification obligation | ||||||
| Name | Hutchison Healthcare Holdings Limited | |||||
| City and country of registered office (if applicable) | British Virgin Islands | |||||
| 4. Full name of shareholder(s) (if different from 3.) | ||||||
| Name | ||||||
| City and country of registered office (if applicable) | ||||||
| 5. Date on which the threshold was crossed or reached: | 02/07/2019 | |||||
| 6. Date on which issuer notified (DD/MM/YYYY): | 02/07/2019 | |||||
| 7. Total positions of person(s) subject to the notification obligation | ||||||
| % of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) |
Total of both in % (8.A + 8.B) | Total number of voting rights of issuer | |||
| Resulting situation on the date on which threshold was crossed or reached | 51.15% | 51.15% | 666,577,450 | |||
| Position of previous notification (if applicable) | 60.36% | – | 60.36% | |||
| 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached | |||||||||
| A: Voting rights attached to shares | |||||||||
| Class/type of sharesISIN code (if possible) |
Number of voting rights | % of voting rights | |||||||
|
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
||||||
| Ordinary Shares (KYG4672N1198) |
340,978,770 | – | 51.15% | – | |||||
| American Depositary Shares (US44842L1035) |
– | – | – | – | |||||
| SUBTOTAL 8. A | 340,978,770 | 51.15% | |||||||
| B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) | |||||||||
| Type of financial instrument | Expiration datex |
Exercise/ Conversion Period |
Number of voting rights that may be acquired if the instrument is exercised/converted. | % of voting rights | |||||
| SUBTOTAL 8. B 1 | |||||||||
| B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) | |||||||||||
| Type of financial instrument | Expiration datex |
Exercise/ Conversion Period |
Physical or cash settlement | Number of voting rights | % of voting rights | ||||||
| SUBTOTAL 8.B.2 | |||||||||||
| 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”) | ||||
| Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer | ||||
| Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) |
X | |||
| Name | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
| CK Hutchison Holdings Limited – indirect, but ultimate, owner of the shareholder | 51.15% | 51.15% | ||
| Hutchison Whampoa (China) Limited – direct owner of the shareholder and a subsidiary of CK Hutchison Holdings Limited | 51.15% | 51.15% | ||
| 10. In case of proxy voting, please identify: | ||||
| Name of the proxy holder | ||||
| The number and % of voting rights held | ||||
| The date until which the voting rights will be held | ||||
| 11. Additional information | ||||
|
|
||||
| Place of completion | Hong Kong |
| Date of completion | 3 July 2019 |
| NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) | ||||||
| 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: |
Hutchison China MediTech Limited; Legal Entity Identifier: 2138006X34YDQ6OBYE79 |
|||||
| 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) | ||||||
| Non-UK issuer | X | |||||
| 2. Reason for the notification (please mark the appropriate box or boxes with an “X”) | ||||||
| An acquisition or disposal of voting rights | X | |||||
| An acquisition or disposal of financial instruments | ||||||
| An event changing the breakdown of voting rights | ||||||
| Other (please specify): | ||||||
| 3. Details of person subject to the notification obligation | ||||||
| Name | Prudential plc group of companies | |||||
| City and country of registered office (if applicable) | London, United Kingdom | |||||
| 4. Full name of shareholder(s) (if different from 3.) | ||||||
| Name | ||||||
| City and country of registered office (if applicable) | ||||||
| 5. Date on which the threshold was crossed or reached: | 28/06/2019 | |||||
| 6. Date on which issuer notified (DD/MM/YYYY): | 01/07/2019 | |||||
| 7. Total positions of person(s) subject to the notification obligation | ||||||
| % of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) |
Total of both in % (8.A + 8.B) | Total number of voting rights of issuer | |||
| Resulting situation on the date on which threshold was crossed or reached | 5.10% | 0.00% | 5.10% | 666,577,450 | ||
| Position of previous notification (if applicable) | N/A | N/A | N/A | |||
| 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached | |||||||||
| A: Voting rights attached to shares | |||||||||
| Class/type of sharesISIN code (if possible) |
Number of voting rights | % of voting rights | |||||||
|
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
||||||
| ORD USD0.10 KYG4672N1198 |
10,899,950 | 1.63% | |||||||
| SPON ADS US44842L1035 |
23,141,235 | 3.47% | |||||||
| SUBTOTAL 8. A | 34,041,185 | 5.10% | |||||||
| 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”) | ||||
| Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer | ||||
| Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) |
X | |||
| Name | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
|
Prudential plc (Parent Company) |
5.10% | 0.00% | 5.10% | |
|
M&G Prudential Limited (wholly owned subsidiary of Prudential plc) |
5.10% | 0.00% | 5.10% | |
|
M&G Group Limited (wholly owned subsidiary of Prudential plc) |
5.10% | 0.00% | 5.10% | |
|
M&G Limited (wholly owned subsidiary of M&G Group Limited) |
5.10% | 0.00% | 5.10% | |
|
M&G Investment Management Limited (wholly owned subsidiary of M&G Limited) |
5.10% | 0.00% | 5.10% | |
| 10. In case of proxy voting, please identify: | ||||
| Name of the proxy holder | N/A | |||
| The number and % of voting rights held | N/A | |||
| The date until which the voting rights will be held | N/A | |||
| 11. Additional information | ||||
|
|
||||
| Place of completion | London, United Kingdom |
| Date of completion | 01 July 2019 |
London: Wednesday, July 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2019 on Tuesday, July 30, 2019 at 7:00 am British Summer Time (BST) (2:00 pm Hong Kong Time (HKT); 2:00 am Eastern Daylight Time (EDT)).
An analyst presentation will be held at 9:00 am BST (4:00 pm HKT) on the same day at Citigate Dewe Rogerson, 8th Floor, Holborn Gate, 26 Southampton Buildings, London WC2A 1AN, UK, which will be webcast via the company website at www.chi-med.com/investors/event-information/. The presentation will be available to download before the analyst presentation begins.
For North America based analysts and investors, Chi-Med will also host a conference call with Q&A at 9:00 am EDT (2:00 pm BST).
Details of the analyst presentation and conference call dial-in will be provided in the financial results announcement. A replay will also be available on the website shortly after each event.
Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 440 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med’s Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.
Chi-Med is headquartered in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.
Mark Lee, Senior Vice President, Corporate Finance & Development
+852 2121 8200
Annie Cheng, Vice President, Corporate Finance & Development
+1 (973) 567 3786
David Dible, Citigate Dewe Rogerson
+44 7967 566 919 (Mobile)
david.dible@citigatedewerogerson.com
Xuan Yang, Solebury Trout
+1 (415) 971 9412 (Mobile)
xyang@troutgroup.com
UK & Europe – Anthony Carlisle, Citigate Dewe Rogerson
+44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
Americas – Brad Miles, Solebury Trout
+1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Hong Kong & Asia ex-China – Joseph Chi Lo, Brunswick
+852 9850 5033 (Mobile)
jlo@brunswickgroup.com
Hong Kong & Asia ex-China – Zhou Yi, Brunswick
+852 9783 6894 (Mobile)
yzhou@brunswickgroup.com
Mainland China – Sam Shen, Edelman
+86 1367 179 1029 (Mobile)
sam.shen@edelman.com
Richard Gray / Atholl Tweedie, Panmure Gordon (UK) Limited
+44 (20) 7886 2500